<DOC>
	<DOCNO>NCT01221402</DOCNO>
	<brief_summary>Intermediate saphenous vein graft ( SVG ) lesion common , high rate progression severe lesion occlusion , associate high incidence adverse clinical outcome . The ALPINE-SVG trial randomized-controlled trial extended-release niacin vs. placebo patient intermediate saphenous vein graft lesion . The main hypothesis study compare placebo , niacin administration result reduction percent atheroma volume 12-month follow-up angiography .</brief_summary>
	<brief_title>Effect Extended-Release Niacin Saphenous Vein Graft Atherosclerosis</brief_title>
	<detailed_description>This phase II , single-center , double-blind trial randomize 138 prior CABG patient intermediate SVG lesion ( 30 % -60 % angiographic diameter stenosis ) clinically-indicated coronary angiography , HDL-C &lt; 60 mg/dL ER-niacin dose 1500-2000 mg daily match placebo ( contain 50 mg niacin cause flush lipid lower effect ) 12 month . All patient receive statin goal LDL-C &lt; 70 mg/dL . Coronary angiography , intravascular ultrasonography ( IVUS ) , intravascular near-infrared intracoronary spectroscopy ( NIRS ) , optical coherence tomography ( OCT ) intermediate SVG lesion perform enrollment 12 month patient , along exercise stress test 1 month 12 month , B-mode carotid ultrasound image enrollment 6 12 month , reactive hyperemia peripheral arterial tonometry ( RH-PAT ) enrollment 6 12 month , peripheral blood sampling perform enrollment 1 , 3 , 6 , 9 12 month , determine whether compare placebo , administration ER-niacin result : 1 . Reduction percent atheroma volume ( PAV ) intermediate SVG lesion 12-month follow-up IVUS imaging ( primary endpoint ) 2 . Reduction total normalized total intermediate SVG lesion atheroma volume , reduction atheroma volume diseased 10-mm subsegment target intermediate lesion , reduction atheroma volume subsegment target intermediate lesion lipid core plaque NIRS , reduction lipid core burden index assess near-infrared intracoronary spectroscopy , increase fibrous cap thickness reduction prevalence number microchannels , presence extent necrotic lipid pool , plaque rupture , calcification , thrombus , assess optical coherence tomography , reduction angiographic intermediate SVG target lesion failure 12-month follow-up SVG imaging ( secondary endpoint ) 3 . Increased exercise capacity reduction ischemia , assess exercise stress test 1 12 month ( secondary endpoint ) 4 . Less increase mean carotid intima-media thickness 6 12 month ( secondary endpoint ) 5 . Greater increase natural logarithmic scale reactive hyperemia index ( L_RHI ) 6 12 month ( secondary endpoint ) 6 . Greater increase EPC-CFU/mL peripheral blood baseline 1 , 3 , 6 , 12 month post enrollment ( secondary endpoint ) 7 . Reduction major adverse cardiac event ( define composite death , acute coronary syndrome , coronary revascularization ) follow-up ( secondary endpoint )</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Age 18 year great 2 . Willing able give inform consent . The patient must able comply study procedure followup . 3 . Undergoing clinicallyindicated coronary SVG angiography 4 . Have intermediate SVG lesion ( define lesion 3060 % angiographic diameter stenosis ) without previous percutaneous intervention , amenable examination IVUS . The lesion thrombus ulceration consider responsible patient 's clinical presentation referral graft angiography . 1 . Known allergy niacin 2 . History statininduced myopathy 3 . Positive pregnancy test breastfeed 4 . Coexisting condition limit life expectancy le 12 month could affect patient 's compliance protocol 5 . Uncontrolled fasting triglyceride level ( 500 mg/dL ) 6 . Fasting LDLC &gt; 200 mg/dL 7 . Fasting HDLC &gt; 60 mg/dL 8 . Poorly control diabetes ( glycosylated hemoglobin level 10 % ) 9 . Current active liver disease hepatic dysfunction 10 . AST ALT &gt; 2x upper limit normal 11 . Uncontrolled hypothyroidism ( Thyroid Stimulating Hormone &gt; 1.5 x upper limit normal [ ULN ] ) 12 . Unexplained creatine kinase elevation ( &gt; 3 x ULN ) 13 . Recent history acute gout 14 . Serum creatinine &gt; 2.5 mg/dL 15 . HIV ( due potential antiretroviral druginteractions niacin ) 16 . Use highdose , antioxidant vitamin ( vitamin C , E , betacarotene ) may interfere HDLraising effect niacin 17 . Severe peripheral arterial disease limit vascular access 18 . Referral cardiac catheterization physician investigator present study . 19 . Symptoms consistent moderate great severity congestive heart failure ( New York Heart Association NYHA class III IV ) whose recent determination leave ventricular ejection fraction &lt; 25 % 20 . Uncontrolled hypertension , define either rest diastolic blood pressure ≥100 mmHg rest systolic blood pressure ≥200 mmHg 21 . History allergic reaction iodinebased contrast agent 22 . Significant medical psychological condition , opinion investigator , may compromise patient 's safety successful participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>